JP2023159323A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2023159323A5 JP2023159323A5 JP2023135127A JP2023135127A JP2023159323A5 JP 2023159323 A5 JP2023159323 A5 JP 2023159323A5 JP 2023135127 A JP2023135127 A JP 2023135127A JP 2023135127 A JP2023135127 A JP 2023135127A JP 2023159323 A5 JP2023159323 A5 JP 2023159323A5
- Authority
- JP
- Japan
- Prior art keywords
- vegf antagonist
- patient
- diabetic retinopathy
- score
- visual acuity
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2025013470A JP2025069279A (ja) | 2017-11-30 | 2025-01-30 | 血管形成眼障害を処置するためのｖｅｇｆアンタゴニストの使用 |
Applications Claiming Priority (8)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762593033P | 2017-11-30 | 2017-11-30 | |
| US62/593,033 | 2017-11-30 | ||
| US201862644425P | 2018-03-17 | 2018-03-17 | |
| US62/644,425 | 2018-03-17 | ||
| US201862748782P | 2018-10-22 | 2018-10-22 | |
| US62/748,782 | 2018-10-22 | ||
| JP2020526625A JP7339248B2 (ja) | 2017-11-30 | 2018-11-29 | 血管形成眼障害を処置するためのｖｅｇｆアンタゴニストの使用 |
| PCT/US2018/063025 WO2019108770A1 (en) | 2017-11-30 | 2018-11-29 | Use of a vegf antagonist to treat angiogenic eye disorders |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020526625A Division JP7339248B2 (ja) | 2017-11-30 | 2018-11-29 | 血管形成眼障害を処置するためのｖｅｇｆアンタゴニストの使用 |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025013470A Division JP2025069279A (ja) | 2017-11-30 | 2025-01-30 | 血管形成眼障害を処置するためのｖｅｇｆアンタゴニストの使用 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2023159323A JP2023159323A (ja) | 2023-10-31 |
| JP2023159323A5 true JP2023159323A5 (https=) | 2024-02-08 |
Family
ID=64755724
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020526625A Active JP7339248B2 (ja) | 2017-11-30 | 2018-11-29 | 血管形成眼障害を処置するためのｖｅｇｆアンタゴニストの使用 |
| JP2023135127A Pending JP2023159323A (ja) | 2017-11-30 | 2023-08-23 | 血管形成眼障害を処置するためのｖｅｇｆアンタゴニストの使用 |
| JP2025013470A Pending JP2025069279A (ja) | 2017-11-30 | 2025-01-30 | 血管形成眼障害を処置するためのｖｅｇｆアンタゴニストの使用 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020526625A Active JP7339248B2 (ja) | 2017-11-30 | 2018-11-29 | 血管形成眼障害を処置するためのｖｅｇｆアンタゴニストの使用 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025013470A Pending JP2025069279A (ja) | 2017-11-30 | 2025-01-30 | 血管形成眼障害を処置するためのｖｅｇｆアンタゴニストの使用 |
Country Status (25)
| Country | Link |
|---|---|
| US (3) | US10973879B2 (https=) |
| EP (4) | EP4122486A1 (https=) |
| JP (3) | JP7339248B2 (https=) |
| KR (2) | KR20200093621A (https=) |
| CN (1) | CN111465407A (https=) |
| AU (2) | AU2018375398C1 (https=) |
| BR (1) | BR112020010659A2 (https=) |
| CA (1) | CA3083611A1 (https=) |
| DK (1) | DK3716992T3 (https=) |
| ES (1) | ES2927049T3 (https=) |
| HR (1) | HRP20221335T1 (https=) |
| HU (1) | HUE059827T2 (https=) |
| IL (3) | IL312323B1 (https=) |
| LT (1) | LT3716992T (https=) |
| MX (1) | MX2020005166A (https=) |
| MY (1) | MY201127A (https=) |
| NZ (1) | NZ764953A (https=) |
| PL (1) | PL3716992T3 (https=) |
| PT (1) | PT3716992T (https=) |
| RS (1) | RS63703B1 (https=) |
| SG (1) | SG11202004268PA (https=) |
| SI (1) | SI3716992T1 (https=) |
| SM (1) | SMT202200374T1 (https=) |
| WO (1) | WO2019108770A1 (https=) |
| ZA (1) | ZA202002821B (https=) |
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2494108C2 (ru) | 2006-04-07 | 2013-09-27 | Аерпио Терапетикс, Инк. | Антитела, которые связывают человеческий белок бета-тирозин фосфатазу (нртрвета), и их использование |
| KR20190049934A (ko) | 2011-01-13 | 2019-05-09 | 리제너론 파아마슈티컬스, 인크. | 혈관신생 눈 장애를 치료하기 위한 vegf 길항제의 용도 |
| WO2013056240A1 (en) | 2011-10-13 | 2013-04-18 | Aerpio Therapeutics, Inc. | Methods for treating vascular leak syndrome and cancer |
| WO2017096031A1 (en) | 2015-12-03 | 2017-06-08 | Regeneron Pharmaceuticals, Inc. | Methods of associating genetic variants with a clinical outcome in patients suffering from age-related macular degeneration treated with anti-vegf |
| HUE059827T2 (hu) | 2017-11-30 | 2023-01-28 | Regeneron Pharma | VEGF-antagonista alkalmazása angiogén szembetegségek kezelésére |
| DK4364724T3 (da) | 2018-05-10 | 2025-12-22 | Regeneron Pharma | Formuleringer med høj koncentration af VEGF-receptorfusionsprotein |
| US11519020B2 (en) | 2018-05-25 | 2022-12-06 | Regeneron Pharmaceuticals, Inc. | Methods of associating genetic variants with a clinical outcome in patients suffering from age-related macular degeneration treated with anti-VEGF |
| WO2020068653A1 (en) | 2018-09-24 | 2020-04-02 | Aerpio Pharmaceuticals, Inc. | MULTISPECIFIC ANTIBODIES THAT TARGET HPTP - β (VE-PTP) AND VEGF |
| EP3886946A1 (en) | 2019-06-05 | 2021-10-06 | Regeneron Pharmaceuticals, Inc. | Devices and methods for precision dose delivery |
| US10975169B1 (en) * | 2019-09-27 | 2021-04-13 | Memorial Sloan Kettering Cancer Center | Methods for treating diabetic retinopathy using anti-ceramide monoclonal antibody 2A2 |
| AU2021268026A1 (en) | 2020-05-08 | 2023-01-19 | Regeneron Pharmaceuticals, Inc. | VEGF traps and mini-traps and methods for treating ocular disorders and cancer |
| US11944663B2 (en) * | 2020-06-18 | 2024-04-02 | Chengdu Kanghong Biotechnologies Co. Ltd. | Method for treating angiogenic eye disorders using VEGF antagonists |
| WO2022120168A1 (en) * | 2020-12-04 | 2022-06-09 | Genentech, Inc. | Automated screening for diabetic retinopathy severity using color fundus image data |
| AU2022251523A1 (en) * | 2021-03-31 | 2023-09-28 | Hangzhou Exegenesis Bio Ltd. | Fusion molecules targeting vegf and angiopoietin and uses thereof |
| KR20240008821A (ko) * | 2021-05-17 | 2024-01-19 | 리제너론 파아마슈티컬스, 인크. | 혈관신생성 눈 장애 치료를 위한 연장된 고용량 vegf 길항제 요법 |
| IL315347A (en) * | 2022-03-15 | 2024-11-01 | Regeneron Pharma | Prolonged high-dose VEGF antagonist regimens for the treatment of angiogenic ocular disorders |
| USD1120314S1 (en) | 2022-11-30 | 2026-03-24 | Regeneron Pharmaceuticals, Inc. | Dose delivery device |
| CN120060370A (zh) * | 2023-11-29 | 2025-05-30 | 上海科锐克医药科技有限公司 | 用于递送人vegf受体融合蛋白的基因递送载体及其应用 |
Family Cites Families (54)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2434840T3 (es) | 1995-07-27 | 2013-12-17 | Genentech, Inc. | Formulación de proteína liofilizada isotónica estable |
| US6100071A (en) | 1996-05-07 | 2000-08-08 | Genentech, Inc. | Receptors as novel inhibitors of vascular endothelial growth factor activity and processes for their production |
| CA2262817A1 (en) | 1996-08-19 | 1998-02-26 | James Robl | Embryonic or stem-like cell lines produced by cross species nuclear transplantation |
| US6171586B1 (en) | 1997-06-13 | 2001-01-09 | Genentech, Inc. | Antibody formulation |
| US7396664B2 (en) | 1999-06-08 | 2008-07-08 | Regeneron Pharmaceuticals, Inc. | VEGF-binding fusion proteins and nucleic acids encoding the same |
| US7303746B2 (en) | 1999-06-08 | 2007-12-04 | Regeneron Pharmaceuticals, Inc. | Methods of treating eye disorders with modified chimeric polypeptides |
| US6833349B2 (en) | 1999-06-08 | 2004-12-21 | Regeneron Pharmaceuticals, Inc. | Methods of treating inflammatory skin diseases |
| US7070959B1 (en) | 1999-06-08 | 2006-07-04 | Regeneron Pharmaceuticals, Inc. | Modified chimeric polypeptides with improved pharmacokinetic properties |
| US7306799B2 (en) * | 1999-06-08 | 2007-12-11 | Regeneron Pharmaceuticals, Inc. | Use of VEGF inhibitors for treatment of eye disorders |
| US7087411B2 (en) | 1999-06-08 | 2006-08-08 | Regeneron Pharmaceuticals, Inc. | Fusion protein capable of binding VEGF |
| CN101433715B (zh) | 1999-06-08 | 2013-04-17 | 里珍纳龙药品有限公司 | 具有改善的药物动力学特性的修饰嵌合多肽 |
| MXPA04000747A (es) | 2001-07-25 | 2004-07-08 | Protein Desing Labs Inc | Formulacion farmaceutica liofilizada estable de anticuerpos igg. |
| IL161677A0 (en) | 2001-11-08 | 2004-09-27 | Protein Design Labs | Stable liquid pharmaceutical formulation of igg antibodies |
| JP2005511576A (ja) | 2001-11-09 | 2005-04-28 | アイテック・ファーマシューティカルズ | 眼球血管新生病を治療する方法 |
| AU2003226349B2 (en) | 2002-04-11 | 2008-01-31 | Children's Medical Center Corporation | Methods for inhibiting vascular hyperpermeability |
| WO2004072320A2 (en) | 2003-02-07 | 2004-08-26 | Pavco, Inc. | Use of n-allyl substituted amines and their salts as brightening agents in nickel plating baths |
| WO2004087206A2 (en) | 2003-03-28 | 2004-10-14 | Regeneron Pharmaceuticals, Inc. | Methods of treating diabetes by blocking vegf-mediated activity |
| MXPA05010555A (es) | 2003-04-04 | 2006-03-09 | Genentech Inc | Formulaciones de proteina y anticuerpo de alta concentracion. |
| WO2004103159A2 (en) | 2003-05-14 | 2004-12-02 | The Board Of Trustees Of The Leland Stanford Junior University | Methods for modulating endometrium |
| CA2519835A1 (en) | 2003-05-28 | 2004-12-09 | Regeneron Pharmaceuticals, Inc. | Method of treating corneal transplant rejection |
| AR046510A1 (es) | 2003-07-25 | 2005-12-14 | Regeneron Pharma | Composicion de un antagonista de vegf y un agente anti-proliferativo |
| EP1732947B1 (en) | 2004-03-05 | 2011-04-27 | Vegenics Pty Ltd | Growth factor binding constructs materials and methods |
| CN100361710C (zh) | 2004-06-07 | 2008-01-16 | 成都康弘生物科技有限公司 | 肿瘤细胞专一表达免疫调节因子gm-csf的溶瘤性腺病毒重组体的构建及其应用 |
| CN1304427C (zh) | 2004-06-08 | 2007-03-14 | 成都康弘生物科技有限公司 | 抑制血管新生的融合蛋白质及其用途 |
| EP1767546B1 (en) | 2004-06-08 | 2012-03-07 | Chengdu Kanghong Biotechnologies Co., Ltd. | Angiogenesis-inhibiting chimeric protein and the use |
| CA2567686A1 (en) | 2004-06-10 | 2005-12-29 | Regeneron Pharmaceuticals, Inc. | Use of vegf inhibitors for the treatment of human cancer |
| MXPA06014689A (es) | 2004-06-18 | 2008-03-11 | Regeneron Pharma | Inhibidores del vegf para el tratamiento de efusion pleural maligna. |
| AU2005267741A1 (en) | 2004-07-30 | 2006-02-09 | Regeneron Pharmaceuticals, Inc. | Methods of treating type I diabetes by blocking VEGF-mediated activity |
| PT1802334E (pt) | 2004-10-21 | 2012-11-28 | Genentech Inc | Método para tratamento de doenças neovasculares intraoculares |
| US7303748B2 (en) | 2005-02-02 | 2007-12-04 | Regeneron Pharmaceuticals, Inc. | Method of treating eye injury with local administration of a VEGF inhibitor |
| ES2633574T3 (es) | 2005-03-25 | 2017-09-22 | Regeneron Pharmaceuticals, Inc. | Formulaciones de antagonistas de VEGF |
| CA2615636A1 (en) | 2005-08-12 | 2007-02-22 | Regeneron Pharmaceuticals, Inc. | Treatment of diseases by subcutaneous administration of a vegf antagonist |
| CN100567325C (zh) | 2006-03-31 | 2009-12-09 | 成都康弘生物科技有限公司 | Vegf受体融合蛋白及其在制备治疗眼睛疾病的药物中的应用 |
| US8216575B2 (en) | 2006-03-31 | 2012-07-10 | Chengdu Kanghong Biotechnologies Co., Ltd. | Inhibition of neovascularization with a soluble chimeric protein comprising VEGF FLT-1 and KDR domains |
| CN100502945C (zh) | 2006-03-31 | 2009-06-24 | 成都康弘生物科技有限公司 | Vegf受体融合蛋白在治疗眼睛疾病中的应用 |
| CA2654510C (en) | 2006-06-16 | 2015-03-17 | Regeneron Pharmaceuticals, Inc. | Vegf antagonist formulations suitable for intravitreal administration |
| US20100111963A1 (en) | 2006-11-10 | 2010-05-06 | Genentech, Inc. | Method for treating age-related macular degeneration |
| FR2918279B1 (fr) | 2007-07-05 | 2010-10-22 | Aventis Pharma Sa | Combinaisons antitumorales contenant un agent inhibiteur de vegf et de l'irinotecan |
| CN102233132B (zh) | 2010-04-28 | 2013-10-23 | 成都康弘生物科技有限公司 | Vegf受体融合蛋白在制备抑制眼表新生血管生长的药物中的应用 |
| CN102380096B (zh) | 2010-08-31 | 2014-04-30 | 成都康弘生物科技有限公司 | 一种含有抑制血管增生的融合蛋白的药物组合物及用途 |
| KR20190049934A (ko) | 2011-01-13 | 2019-05-09 | 리제너론 파아마슈티컬스, 인크. | 혈관신생 눈 장애를 치료하기 위한 vegf 길항제의 용도 |
| CN103212075B (zh) | 2012-01-19 | 2017-06-27 | 成都康弘生物科技有限公司 | 一种含有vegf拮抗剂的滴眼液 |
| EP3010526A1 (en) * | 2013-06-20 | 2016-04-27 | Novartis AG | Use of a vegf antagonist in treating macular edema |
| DK4374873T3 (da) * | 2013-07-12 | 2025-11-03 | Astellas Us Llc | Middel til brug ved behandling eller forebyggelse af oftalmologiske tilstande |
| MX368442B (es) | 2014-01-25 | 2019-10-02 | Chengdu Kanghong Biotechnologies Co Ltd | Proteína de fusión que inhibe angiogénesis o crecimiento y uso de la misma. |
| TWI806150B (zh) | 2014-11-07 | 2023-06-21 | 瑞士商諾華公司 | 穩定的含有高濃度抗vegf抗體之蛋白質溶液調配物 |
| US20160144025A1 (en) * | 2014-11-25 | 2016-05-26 | Regeneron Pharmaceuticals, Inc. | Methods and formulations for treating vascular eye diseases |
| CA2989270A1 (en) | 2015-06-16 | 2016-12-22 | Translatum Medicus, Inc. | Compositions and methods for treating and diagnosing ocular disorders |
| PE20181363A1 (es) | 2015-09-23 | 2018-08-27 | Genentech Inc | Variantes optimizadas de anticuerpos anti-vegf |
| EP3377100B1 (en) * | 2015-11-18 | 2025-02-26 | Formycon AG | Pre-filled pharmaceutical package comprising a liquid formulation of a vegf-antagonist |
| EP3380121B1 (en) | 2015-11-23 | 2023-12-20 | Acceleron Pharma Inc. | Actrii antagonist for use in treating eye disorders |
| DE102017210134A1 (de) | 2016-12-15 | 2018-06-21 | Fresenius Medical Care Deutschland Gmbh | System zur extrakorporalen Blutbehandlung, Behandlungsvorrichtung, Kit und Verfahren zum Betreiben eines Systems zur extrakorporalen Blutbehandlung |
| HUE059827T2 (hu) | 2017-11-30 | 2023-01-28 | Regeneron Pharma | VEGF-antagonista alkalmazása angiogén szembetegségek kezelésére |
| DK4364724T3 (da) | 2018-05-10 | 2025-12-22 | Regeneron Pharma | Formuleringer med høj koncentration af VEGF-receptorfusionsprotein |
-
2018
- 2018-11-29 HU HUE18825837A patent/HUE059827T2/hu unknown
- 2018-11-29 EP EP22181390.0A patent/EP4122486A1/en not_active Withdrawn
- 2018-11-29 CA CA3083611A patent/CA3083611A1/en active Pending
- 2018-11-29 SI SI201830749T patent/SI3716992T1/sl unknown
- 2018-11-29 SG SG11202004268PA patent/SG11202004268PA/en unknown
- 2018-11-29 US US16/204,262 patent/US10973879B2/en active Active
- 2018-11-29 LT LTEPPCT/US2018/063025T patent/LT3716992T/lt unknown
- 2018-11-29 MX MX2020005166A patent/MX2020005166A/es unknown
- 2018-11-29 PL PL18825837.0T patent/PL3716992T3/pl unknown
- 2018-11-29 KR KR1020207018642A patent/KR20200093621A/ko not_active Ceased
- 2018-11-29 IL IL312323A patent/IL312323B1/en unknown
- 2018-11-29 JP JP2020526625A patent/JP7339248B2/ja active Active
- 2018-11-29 WO PCT/US2018/063025 patent/WO2019108770A1/en not_active Ceased
- 2018-11-29 SM SM20220374T patent/SMT202200374T1/it unknown
- 2018-11-29 IL IL326641A patent/IL326641A/en unknown
- 2018-11-29 MY MYPI2020002624A patent/MY201127A/en unknown
- 2018-11-29 EP EP25172993.5A patent/EP4609914A3/en active Pending
- 2018-11-29 ES ES18825837T patent/ES2927049T3/es active Active
- 2018-11-29 EP EP23187537.8A patent/EP4279135A3/en active Pending
- 2018-11-29 HR HRP20221335TT patent/HRP20221335T1/hr unknown
- 2018-11-29 IL IL274711A patent/IL274711B2/en unknown
- 2018-11-29 PT PT188258370T patent/PT3716992T/pt unknown
- 2018-11-29 DK DK18825837.0T patent/DK3716992T3/da active
- 2018-11-29 CN CN201880077100.0A patent/CN111465407A/zh active Pending
- 2018-11-29 AU AU2018375398A patent/AU2018375398C1/en active Active
- 2018-11-29 EP EP18825837.0A patent/EP3716992B1/en active Active
- 2018-11-29 RS RS20221003A patent/RS63703B1/sr unknown
- 2018-11-29 BR BR112020010659-3A patent/BR112020010659A2/pt unknown
- 2018-11-29 NZ NZ764953A patent/NZ764953A/en unknown
- 2018-11-29 KR KR1020247015825A patent/KR20240074890A/ko active Pending
-
2020
- 2020-05-15 ZA ZA2020/02821A patent/ZA202002821B/en unknown
-
2021
- 2021-01-13 US US17/148,039 patent/US12280093B2/en active Active
-
2023
- 2023-08-23 JP JP2023135127A patent/JP2023159323A/ja active Pending
-
2025
- 2025-01-17 US US19/027,504 patent/US20250268983A1/en active Pending
- 2025-01-30 JP JP2025013470A patent/JP2025069279A/ja active Pending
- 2025-02-19 AU AU2025201179A patent/AU2025201179A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2023159323A5 (https=) | ||
| JP2021505535A5 (https=) | ||
| IL312323A (en) | Use of VEGF antagonist to treat angiogenic eye disorders | |
| Hussain et al. | Vascular endothelial growth factor antagonists: promising players in the treatment of neovascular age-related macular degeneration | |
| JP7503590B2 (ja) | 遺伝子構築物 | |
| Khalin et al. | Targeted delivery of brain-derived neurotrophic factor for the treatment of blindness and deafness | |
| JP2015523060A5 (https=) | ||
| JP2020535184A5 (https=) | ||
| RU2014150340A (ru) | Лечение amd с применением экспессируемого aav sflt-1 | |
| Stewart | Aflibercept (VEGF Trap-Eye) for the treatment of exudative age-related macular degeneration | |
| Xu et al. | Intravitreal Conbercept Injection with and without Grid Laser Photocoagulation in the Treatment of Diffuse Diabetic Macular Edema in Real‐Life Clinical Practice | |
| JP2024519629A5 (https=) | ||
| JP2021511030A5 (https=) | ||
| Dahrouj et al. | Receptor mediated disruption of retinal pigment epithelium function in acute glycated-albumin exposure | |
| Elshaer et al. | Implication of the neurotrophin receptor p75NTR in vascular diseases: beyond the eye | |
| CN119585299A (zh) | 编码抗vegf实体和补体负调节剂的核酸及其用于年龄相关性黄斑变性的治疗的用途 | |
| Jianjiang et al. | Progress of anti-vascular endothelial growth factor therapy for ocular neovascular disease: benefits and challenges | |
| Zou et al. | Lasting controversy on ranibizumab and bevacizumab | |
| Irani et al. | An anti–VEGF-B antibody fragment induces regression of pre-existing blood vessels in the rat cornea | |
| Vasilaki et al. | Effect of somatostatin on nitric oxide production in human retinal pigment epithelium cell cultures | |
| Unsal et al. | The results of aflibercept therapy as a first line treatment of age-related macular degeneration | |
| Abrishami et al. | Unilateral acute central serous chorioretinopathy with inactivated coronavirus disease 2019 vaccination: A case report and review of literature | |
| Park et al. | Proliferative retinopathy developed in a duchenne muscular dystrophy patient with normal cardiac function | |
| JP2025501913A (ja) | 血管新生阻害剤結合抗Ｃ３ｂ抗体又は抗Ｃ５抗体及びその使用 | |
| JP2020518641A5 (https=) |